Celebrex Ads Were Misleading, FDA Says
From Times Wire Reports
Advertisements for the arthritis drug Celebrex were misleading and unsubstantiated, overstating the pain reliever’s benefits and understating the risks, the Food and Drug Administration said.
The agency asked for an immediate halt to all ads for Celebrex, which Pfizer Inc. did last month in advance of the agency’s letter. A study in December found high doses of Celebrex were associated with an increased risk of heart attack.
The letter details the claims in ads for Celebrex and a related drug, Bextra, that appeared on television, in print, on TV infomercials and in mail brochures.
